KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Tax Provisions (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 14 years of Tax Provisions data on record, last reported at -$242.4 million in Q3 2025.

  • For Q3 2025, Tax Provisions fell 1567.93% year-over-year to -$242.4 million; the TTM value through Sep 2025 reached -$332.0 million, down 398.39%, while the annual FY2025 figure was -$272.4 million, 197.94% down from the prior year.
  • Tax Provisions reached -$242.4 million in Q3 2025 per JAZZ's latest filing, down from -$17.2 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $228.6 million in Q2 2021 and bottomed at -$242.4 million in Q3 2025.
  • Average Tax Provisions over 5 years is -$23.0 million, with a median of -$17.6 million recorded in 2021.
  • Peak YoY movement for Tax Provisions: skyrocketed 317.44% in 2021, then plummeted 2958.96% in 2023.
  • A 5-year view of Tax Provisions shows it stood at -$12.5 million in 2021, then tumbled by 702.19% to -$100.0 million in 2022, then soared by 66.9% to -$33.1 million in 2023, then plummeted by 74.96% to -$57.9 million in 2024, then crashed by 318.57% to -$242.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were -$242.4 million in Q3 2025, -$17.2 million in Q2 2025, and -$57.9 million in Q4 2024.